Abstract
ABSTRACTCell morphology is a fundamental feature used to evaluate patient specimens in pathological analysis. However, traditional cytopathology analysis of patient effusion samples is limited by low tumor cell abundance coupled with high background of non-malignant cells, restricting the ability for downstream molecular and functional analyses to identify actionable therapeutic targets. We applied the Deepcell platform that combines microfluidic sorting, brightfield imaging, and real-time deep learning interpretations based on multi-dimensional morphology to enrich carcinoma cells from malignant effusions without cell staining or labels. Carcinoma cell enrichment was validated with whole genome sequencing and targeted mutation analysis, which showed higher sensitivity for detection of tumor fractions and critical somatic variant mutations that were initially at low-levels or undetectable in pre-sort patient samples. Combined, our study demonstrates the feasibility and added value of supplementing traditional morphology-based cytology with deep learning, multi-dimensional morphology analysis, and microfluidic sorting.
Publisher
Cold Spring Harbor Laboratory
Reference62 articles.
1. An Unbiased Cell Morphology–Based Screen for New, Biologically Active Small Molecules
2. Morphological Changes of Cisplatin-resistant Human Breast Cancer MCF-7 Cell Line;International Journal of Integrated Health Sciences,2017
3. Regev, A. et al. The Human Cell Atlas. Elife 6 (2017). https://doi.org:10.7554/eLife.27041
4. Systematic exploration of cell morphological phenotypes associated with a transcriptomic query;Nucleic Acids Res,2018
5. Mirabelli, C. et al. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. Proc Natl Acad Sci U S A 118 (2021). https://doi.org:10.1073/pnas.2105815118
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献